Ogkologos

4396 ΔΗΜΟΣΙΕΥΣΕΙΣ 0 ΣΧΟΛΙΑ

ESMO Welcomes EU Proposals for MFF & FP10 and Calls for...

Ogkologos - 21 Ιουλίου, 2025

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head...

Ogkologos - 18 Ιουλίου, 2025

EMA Recommends Extending Indications for Durvalumab

Ogkologos - 17 Ιουλίου, 2025

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR,...

Ogkologos - 16 Ιουλίου, 2025

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in...

Ogkologos - 16 Ιουλίου, 2025

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell...

Ogkologos - 15 Ιουλίου, 2025

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab...

Ogkologos - 14 Ιουλίου, 2025

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell...

Ogkologos - 11 Ιουλίου, 2025

EMA Recommends Extension of Indications for Cabozantinib

Ogkologos - 10 Ιουλίου, 2025

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation...

Ogkologos - 9 Ιουλίου, 2025

1...444546...440 Σελίδα 45 από 440

MOST POPULAR

Whole-Genome Sequencing Could Help Guide AML Treatment

6 Απριλίου, 2021

Teacher Reads To Students One Day After Having Brain Surgery

26 Οκτωβρίου, 2021

EMA Recommends Granting a Marketing Authorisation for Relacorilant

2 Οκτωβρίου, 2026

Combination immunotherapy for advanced bowel cancer approved for NHS in England

16 Ιουνίου, 2021

Φόρτωση περισσοτέρων

ESMO Welcomes EU Proposals for MFF & FP10 and Calls for...

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head...

EMA Recommends Extending Indications for Durvalumab

Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR,...

Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in...

Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell...

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab...

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell...

EMA Recommends Extension of Indications for Cabozantinib

Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation...

MOST POPULAR

Whole-Genome Sequencing Could Help Guide AML Treatment

Teacher Reads To Students One Day After Having Brain Surgery

EMA Recommends Granting a Marketing Authorisation for Relacorilant

Combination immunotherapy for advanced bowel cancer approved for NHS in England

HOT NEWS

Ovarian, bowel and non-Hodgkin’s lymphoma treatments approved for NHS use in...

Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab...

Efficacy and Safety of Datopotamab Deruxtecan in Patients with Pretreated Advanced/Metastatic...

Should Surgery And Radiation Be The Standard Treatment For DCIS? The...

ΔΗΜΟΦΙΛΕΊΣ ΘΈΣΕΙΣ

ΚΑΡΚΙΝΟΣ ΘΥΜΟΥ ΑΔΕΝΑ (ΘΥΜΩΜΑ)

ΣΤΑΤΙΣΤΙΚΑ

ΚΕΝΤΡΙΚΟΥ ΝΕΥΡΙΚΟΥ ΣΥΣΤΗΜΑΤΟΣ

ΔΗΜΟΦΙΛΗ ΚΑΤΗΓΟΡΙΑ